UNSPSC 51241126: Brimonidine

This classification denotes an anti-glaucoma agent and alpha-adrenergic agonist with the molecular formula C11H10BrN5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E6GNX3HHTE, chemically known as 6-quinoxalinamine, 5-bromo-n-(4,5-dihydro-1h-imidazol-2-yl)- (9ci) but generally known as brimonidine, which bears US NIH Compound Identifier 2435. Brimonidine most often comes in base and tartrate forms.

UNSPSC 51241126 Brimonidine is a Commodity code under which state and local governments procure branded and generic pharmaceutical products—in this case, multi-source generic pharmaceuticals and over-the-counter (OTC) items distributed through established pharmaceutical wholesalers to state agencies and local public facilities. State procurement offices and multistate cooperative purchasing alliances are the primary issuing bodies, leveraging aggregated demand across member jurisdictions to establish master pricing agreements with pharmaceutical manufacturers. Vendors must meet FDA compliance, current Good Manufacturing Practices (cGMP), and Drug Supply Chain Security Act (DSCSA) requirements, maintain authorized relationships with established wholesalers, and offer pricing flexibility through multiple discount structures (flat price, net price formats, or WAC-minus pricing). Insurance requirements include $5 million commercial general liability per occurrence, $2 million network security and privacy liability, and $2 million professional liability coverage. Vendors responding to this code should expect to pay a 3 percent administrative fee on all contract purchases and face performance penalties ranging from $200 to $1,500 per violation for issues including late reporting, missed onboarding timelines, or improper class-of-trade denials.

The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) on behalf of participating state and local government facilities including Oregon, issued an RFP (Solicitation S1070000015802) on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026. Evaluation will weight price competitiveness at 75 percent, fixed pricing for the contract term at 10 percent, compliance with administrative fee data format requirements at 5 percent, EDI capability at 5 percent, and agreement to the 3 percent administrative fee at 5 percent. All products must be available in the marketplace by May 15, 2026, when awarded vendors will be provided to authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), with resulting agreements effective July 1, 2026. The contract term is two years for new responders with optional MMCAP extensions; incumbent responders' amendments align with existing agreement expiration dates through June 30, 2028. Specific award values or budget ranges are not disclosed.